Three patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Aug 2028
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2011 to 2037.201620212026203120362037
4 pending applications: term is not computable until grant.Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2028 · High confidence
Also notable
Ends Jan 2030 · Medium confidence
Also notable
Ends Aug 2037 · Medium confidence
Methods and Compositions for the Treatment of Neuropsychiatric Disorders
US 8,008,283
The most cited patent in this portfolio, cited by 45 later US patents, top 25% of utility patents granted in 2011 in our data. Protection runs to 2028.
Bumetanide Analogs, Compositions and Methods of Use
US 9,682,928
The largest patent family in this portfolio, 10 related applications, renewed at every maintenance window due so far. Protection runs to 2030.
Fan-Out Structure and Method of Fabricating the Same
US 12,020,953
A family of 5 related applications built on the 2024 grant. Too new for citation comparison; protection runs to 2037.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 2 largest of its 3 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Fan-Out Structure and Method of Fabricating the Same | 1 in force | to Aug 2037 |
| Bumetanide Analogs, Compositions and Methods of Use | 1 in force | to Jan 2030 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,008,283 | Methods and Compositions for the Treatment of Neuropsychiatric Disorders In force · High confidence | In force | High confidence | |
| US 9,682,928 | Bumetanide Analogs, Compositions and Methods of Use In force · Medium confidence | In force | Medium confidence | |
| US 12,020,953 | Fan-Out Structure and Method of Fabricating the Same In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 3: 1 patent ended · 4 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.